

Tissue-Specificity and Ethnic Diversity in Obesity-Related Risk of Cancer May Be Explained by Variability in Insulin Response and Insulin Signaling Pathways

John R. Speakman¹ and Michael I. Goran²

Obesity is a predisposing risk factor for several chronic diseases. The link between obesity and cancer appears to be particularly complex. Notably only the risk for development of specific cancers appear to be affected. Moreover, the obesity-related risk of cancer is very different across ethnic groups. African-Americans appear particularly prone, whereas Hispanics appear to be relatively protected. Obesity is associated with increased levels of circulating insulin. These levels of elevated insulin may serve to promote proliferation of fat cells to accommodate the elevated nutrient flux. However, elevated levels of insulin may be a major mediating factor influencing cancer risk. This hypothesis alone cannot explain the complexity of the phenomenon. We suggest here that the different insulin responses to obesity of different ethnic groups may explain their different risk profiles. Moreover, we speculate that tissue-specific variations in the insulin signaling pathways may underlie their differential susceptibility to tumorigenesis in the face of elevated obesity. Elevated cancer risk may be an unwanted side effect of insulin responding to elevated nutrient flux in the obese which it serves to proliferate fat cells that provide a location for storage of ingested fat, which consequently prevents ectopic fat storage. Hence, while Hispanics may be protected from cancer risk in obesity because of their lower insulin response, they have an elevated risk of fatty liver disease. Reduction of insulin levels in obesity as a strategy to reduce cancer risk may pose additional problems unless it is combined also with interventions that aim to limit nutrient influx.

Obesity (2010) **18**, 1071–1078. doi:10.1038/oby.2010.16

BACKGROUND: OBESITY AND ELEVATED DISEASE RISK

Over the past five decades, we have witnessed an enormous increase in levels of body fatness in both the western world, and more recently throughout developing nations (e.g., see refs. 1,2). By the conventional definitions of obesity (BMI >30) and overweight (BMI >25), the population that is obese in the United States has expanded from <5% in 1960 to over 25% in 2004 (3–6). This has been mirrored by an even greater expansion in the numbers of people in the United States that are overweight (increasing from 10 to 35%). However, the largest proportional increase has been in

the morbidly obese (BMI >40) (7). The obesity epidemic has also started to affect people at much younger ages than previously, with childhood rates of obesity on the rise globally (8). Although there are some recent indications that the rate of increase is slowing (9), the trends are still upward in most age groups. Obesity is a major health problem because it increases the risk for a number of chronic illnesses. Perhaps the most significant of these is type 2 diabetes (10). Matched with the increased risk of type 2 diabetes is an elevation of insulin resistance and increased risk for cardiovascular disease (11–13), fatty liver disease (14,15), and cancer (16,17).

The precise mechanisms that link obesity to these chronic diseases is an area of intensive investigation, but as yet there is little consensus on mechanisms of causality, or an understanding of why such links might have evolved. An evolutionary framework that has dominated thinking in this area for almost the past 50 years is the “thrifty gene” hypothesis (18). The “thrifty gene” idea is that historically, human populations were exposed to cyclic periods of feast and famine. Under these conditions, it is suggested that selection would favor individuals that had genes allowing them to rapidly deposit body fat during periods of feast, because these fatter individuals

Both the authors contributed equally to this work.

¹Aberdeen Centre for Energy Regulation and Obesity (ACERO), Institute of Biological and Environmental Sciences, University of Aberdeen, Aberdeen, UK;

²Childhood Obesity Research Center (CORC), University of Southern California, Keck School of Medicine, Los Angeles, California, USA.

Correspondence: John R. Speakman (J.Speakman@abdn.ac.uk)

Received 14 August 2009; accepted 11 January 2010; published online 11 February 2010. doi:10.1038/oby.2010.16

would then have greater reserves to get them through the subsequent periods of famine. Although Neel (18) emphasized increased survival as the primary selective advantage, more recent studies have pointed out that a greater selective benefit may actually be that obese people could retain greater fertility during the famine periods. Neel (18) regarded a mildly diabetic phenotype to be part of this advantageous thrifty genotype helping individuals to deposit fat in times of feast. Obesity and diabetes are then seen as unfortunate consequences of embedding this previously advantageous genotype in a modern environment where food is readily available and easily obtained, allowing individuals to deposit enormous fat reserves in preparation for a famine that may never come (19–26).

This evolutionary framework for understanding the obesity epidemic and the link of obesity to diabetes has recently been called into question (27–30). The thrifty gene idea has several basic flaws. Firstly, if selection really had been so intense, and obesity and diabetes are so advantageous, then it is difficult to understand why the favorable alleles for obesity and diabetes have not spread through the entire population, making us all overweight or obese. Another problem with the “thrifty gene” interpretation that obesity and diabetes were previously selectively advantageous, is the association between obesity and other disorders. Although there might be some merit in the argument that a prediabetic phenotype might enable “thrift” it seems extremely unlikely that the elevated risk of developing cardiovascular disease and cancer in the obese state has any selective advantage. The links between obesity and chronic disease are consequently more likely to result from metabolic consequences that have never been selectively removed, because historically people never got fat enough to precipitate these diseases. Understanding these associations should therefore focus on trying to identify potential molecular linkages between the respective conditions.

Full details of the links between obesity and cancer are presently emerging. It has become clear that obesity does not

uniformly elevate the risk of cancer in all tissues. In particular, the epidemiological links between obesity and cancer are strongest for the following sites: breast cancer, especially postmenopausal breast cancer, endometrial cancer, colon cancer, adenocarcinoma of the esophagus, and renal cell carcinoma (16,17). It is also apparent that in addition to obesity causing differential elevation of risks in different tissues, the risks are also very different between ethnic groups. There are numerous examples of racial differences in cancer risk (31); some examples are shown in **Table 1**.

The mechanism(s) generating these complex tissue-specific and ethnic-specific patterns are currently unclear. One previous hypothesis explaining the link between obesity and cancer relates to elevated insulin levels (32). However, this hypothesis alone is insufficient to explain the diversity in the link between obesity and cancer, that is observed across cancer sites and across different ethnic groups (**Table 1**). Here, we extend this hypothesis beyond the conventional approach of explaining this link through fasting insulin levels or insulin resistance, to other factors involved with insulin, such as postprandial insulin levels throughout the day (i.e., overall exposure of tissues to insulin) as well as downstream factors involved in the insulin signaling process.

EPIDEMIOLOGICAL AND PHYSIOLOGICAL EVIDENCE

Many studies have shown that body fatness is positively associated with

circulating fasting insulin levels in both animals and humans (e.g., see ref. 33). Moreover, obesity results in a state of insulin resistance where increasing amounts of insulin need to be secreted to deal with elevated postprandial circulating blood glucose levels. Body tissues of the obese are therefore continuously exposed to elevated background and glucose stimulated levels of insulin. There is also abundant correlational evidence that circulating insulin levels are associated with cancer risk. For example, chronic caloric restriction results in a profound reduction in circulating insulin levels and disruption of the insulin signaling pathways. In rodents a major consequence of chronic caloric restriction is a reduction in the overall risk of cancer development (34–41). This reduction in cancer risk is hypothesized to be one of the major mediating aspects of the link between reduced food intake and extended longevity in rodents.

Moreover, not only is the reduction of insulin during caloric restriction associated with reduced cancer prevalence, but the ethnic differences in the link between obesity and cancer are also correlated with racial differences in circulating insulin levels. It has long been known for example, that African Americans tend to be hyperinsulinemic (at least compared to whites), and this is also evident during childhood (42). This greater hyperinsulinemia in African Americans is even more striking when insulin is examined in response to glucose. In previous studies in children the insulin response to either oral (43), or intravenous (44)

Table 1 Examples of Ethnic Differences in SEER Incidence Rate for Some Forms of Cancer

Disease outcome	White Non-Hispanic	Hispanic	African American
Cancer ^a (all sites)	494.3	361.6	504.1
Male	573.6	426.2	663.7
Female	320.5	320.5	396.9
Breast cancer ^a	140.2	91.2	118.3
Colon cancer ^a	52.0	39.9	62.1
Prostate cancer ^a	166.6	139.7	255.5
Myeloma ^a	5.1	5.7	11.3

Information abbreviated from Goran MI Ethnic-Specific Pathways to Obesity-Related Disease: The Hispanic vs. African American Paradox. *Obesity* 16: 2561–2565, 2008.

^aCancer data based on NCI SEER incidence rate (2000–2004; age-adjusted rate per 100,000 persons) from http://seer.cancer.gov/cgi-bin/csr/1975_2004/search.pl.

glucose administration is two to three times higher in African Americans compared to whites. These observations are independent of any ethnic difference in body composition or fat distribution and demonstrate profoundly higher levels of insulin in the circulation after oral or intravenous glucose administration, and presumably meal ingestion as well. The elevated insulin response is due partly to higher insulin secretion from β -cells and lower insulin clearance by the liver in African Americans (45). Furthermore, African Americans and Hispanics are more insulin resistant than whites, independent of differences in adiposity, and this difference is evident in childhood (46). Interestingly though, the compensatory response to this similar degree of insulin resistance is quite different in African Americans vs. Hispanics (46). In response to the same degree of insulin resistance, African Americans increase circulating insulin levels by both an increase in β -cell secretion (first-phase

secretion in response to intravenous glucose) and a reduction in liver insulin clearance. Hispanics on the other hand rely solely on β -cell compensation to increase insulin through a secretory response (especially the second-phase insulin response).

HOW MIGHT TISSUE-SPECIFIC VARIATION IN OBESITY-RELATED CANCER RISK BE LINKED TO OVERALL TISSUE EXPOSURE TO INSULIN?

Correlational evidence summarized above supports both a link between obesity and circulating insulin levels, and between these elevated insulin levels and cancer risk. However, these correlations do not show causality. A key outstanding question concerns the mechanism by which elevated circulating insulin could increase the risk of developing cancer, and do so differentially between different tissues, as highlighted in **Table 1**. The insulin signaling pathway is

notoriously complex and has been subject of several recent reviews (47–50). A summary of some key elements of the pathway as they relate to cell cycle and proliferation is shown in **Figure 1**. There are two alternative splice variants of the insulin receptor (IR-A and IR-B) (51). Structurally both receptor isoforms have two extracellular domains and two transmembrane domains. The transmembrane domains are associated with a series of insulin receptor substrate proteins (IRS1–IRS4). In addition, insulin may also bind to the insulin-like growth factor-1 (IGF-1) receptor. Binding of insulin to the extracellular domain of the insulin receptors causes a conformational change which results in the autophosphorylation of several tyrosine residues on the transmembrane domain which are recognized by binding sites on the IRS proteins, leading to phosphorylation of tyrosine residues on these substrate proteins. This phosphorylation leads to stimulation of several intracellular signaling pathways (described in more detail below). The efficiency of transduction of the insulin signal and the specific pathways that are stimulated varies with the receptor isoforms and also with the relative abundance of the different IRS proteins (52–54). The two insulin receptor isoforms, the IGF-1 receptor and the IRS proteins are differentially expressed in different tissues (**Table 2** and see ref. 55). The basis of our hypothesis is that insulin may stimulate cellular proliferation via these numerous pathways in several different ways, and with different efficiencies, depending on the exact balance of the IR isoforms, IRS proteins, and additional regulatory components of the diverse pathways in distinct tissues. Consequently, tissue-to-tissue variation in the stimulation of these diverse pathways might explain the tissue-dependent variable risks of developing cancer in response to obesity. Moreover, we speculate that the ethnic variation in the risk of developing cancer might also be traced to differences in this signaling cascade.

Perhaps the best characterized pathway downstream from insulin is that involving phosphatidylinositol-3 kinase (PI3K) (**Figure 1**). PI3K consists of a regulatory




Figure 1 Some key components of the insulin signaling pathway highlighting links to cyclin-dependent kinase inhibitors p27 and p21 that may mediate a link between insulin and cancer susceptibility. BAD, Bcl-2-associated death promoter; GRB2, growth factor receptor-bound protein-2; GSK, glycogen synthase kinase-3; IGF-1, insulin-like growth factor-1; IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase; Mdm2, mouse double-minute 2; mTOR, mammalian target of rapamycin; NF- κ B, nuclear factor κ B; PIP2, phosphatidylinositol (3,4)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PTEN, phosphatase and tensin homolog; RICTOR, rapamycin insensitive companion of mTOR; SHIP, Src homology 2 domain-containing inositol phosphatase; SKP2, S-phase kinase-associated protein-2.

Table 2 Relative levels of gene expression for the insulin receptor isoforms IR-A and IR-B and the insulin receptor substrates IRS1–IRS3 in different tissues of the rat (data from Serrano *et al.* 2005)

Tissue	IR-A	IR-B	IRS1	IRS2	IRS3
eWAT	38	62	34	27	39
rWAT	49	51	35	28	37
BAT	41	59	40	32	28
SM–S	100	0	37	37	26
SM–WQ	100	0	66	18	16
H	50	50	42	30	28
L	0	100	40	28	32
K	33	67	36	38	26
P	80	20	60	16	24

Figures represent percentage of total expression for the IR and IRS. BAT, brown adipose tissue; eWAT, epididymal white adipose tissue; H, heart; K, kidney; L, liver; P, pancreas; rWAT, retroperitoneal white adipose tissue; SM–S, skeletal muscle soleus; SM–WQ, skeletal muscle white quadriceps.

subunit p85 and a catalytic subunit p110. The regulatory subunit contains a number of Src homology 2 domains that recognize the phosphorylation status of the IRS proteins. Hence, phosphorylation of IRS leads to activation of the catalytic subunit of PI3K which phosphorylates its substrate phosphatidylinositol (3,4)-bisphosphate converting it to phosphatidylinositol (3,4,5)-trisphosphate. This reaction can be reversed by several other enzymes including phosphatase and tensin homolog and Src homology 2 domain-containing inositol phosphatase 1. Increased phosphatidylinositol (3,4,5)-trisphosphate results in activation of AKT (v-akt murine thymoma viral oncogene homolog 1, also known as protein kinase B or PKB) by binding it to the membrane where it can be phosphorylated by 3-phosphoinositide-dependent protein kinase-1. AKT is a key signaling protein that can affect several pathways that may be linked to the cell cycle, and hence proliferation and tumorigenesis (56). One recently discovered important link is via the S-phase kinase-associated protein-2 (SKP2). Skp2 is transcriptionally regulated by PI3K/AKT (57) specifically by regulation of E2F1 binding to the SKP2 promoter (58), although a link via glycogen synthase kinase-3 has also been suggested (59). When activated the main function of SKP2 appears to be to ubiquitinate the protein p27 for degradation by the s26 proteasome (60,61). P27 is a

cyclin-dependent kinase inhibitor which represses the cell cycle. Hence activation of SKP2 removes this repression of the cell cycle and results in elevated proliferation. There is some evidence that SKP2 can also be activated via the mitogen-activated protein kinase (p38 mitogen-activated protein kinase) and ERK1/2 signal transduction pathway (57) which are additional signaling routes linking it to the insulin receptor. Moreover, PI3K and AKT may directly interact with other cyclin-dependent kinases regulating the cell cycle like p21 (58). AKT is established to inhibit mouse double-minute 2 which is a negative regulator of p53, which is itself a key regulator of the cyclin-dependent kinase inhibitor 1A (cyclin-dependent kinase inhibitor 1A or p21). AKT activation may also inhibit apoptosis, via inhibition of glycogen synthase kinase-3 which in addition to activating glycogen synthase is a stimulator of apoptosis. AKT can also mediate reductions in apoptosis in other ways, notably by inhibition of the apoptotic stimulator called Bcl-2-associated death promoter, and via its inhibitory effects on p53 which is also proapoptotic (Figure 1).

There are at least two other pathways via which AKT may affect the cell cycle. First, AKT is a known regulator of the transcription factor nuclear factor κB, which promotes transcription of several genes that stimulate cellular proliferation (62,63). Second, AKT activates

the complex of mammalian target of rapamycin (mTOR) and the regulatory-associated protein of mTOR (mTOR complex 2: mTORC2). This activation may be direct and/or via phosphorylation of TSC2 which is a negative regulator of mTORC2. The mTORC2 complex plays a key role in cellular proliferation (64) because it regulates protein synthesis (via p70 S6kinase) (65). The interactions between mTOR and AKT, however, are multifaceted because mTOR in complex with the rapamycin insensitive companion of mTOR (RICTOR) (mTOR complex 1: mTORC1) negatively regulates AKT.

In addition to the signaling cascade via PI3K and AKT there are other signaling cascades via which insulin may affect cellular proliferation, in particular the p38 mitogen-activated protein kinase (p38 mitogen-activated protein kinase) pathway. This pathway is stimulated directly from the insulin receptor (particularly IR-A), independent of the IRS proteins, via the protein growth factor receptor-bound protein 2 (66) and also can also be stimulated from the IGF-1R. p38 mitogen-activated protein kinase has many downstream effects but these include stimulation of mouse double-minute 2 (hence p53 and p21 inhibition) and also a direct effect on SKP2, hence p27 degradation.

There is considerable evidence from genetic disruption of these pathways that they are associated with cancer risk. For example, global knockout (KO) of IRS1 leads to a long lived mouse with reduced cancer risk, in spite of elevated insulin levels (67), consistent with insulin being the primary mediator of cancer risk, and blunted insulin signaling interfering with this association. Conversely, KO of IRS2 produces a mouse that is profoundly diabetic and dies long before altered susceptibility to cancer could be detected (68), clearly illustrating the different signaling roles played by the different IRS proteins (see also refs. 69,70). The effects of tissue-specific KO of IRS substrates has complex and disputed effects (71,72). Global KO of the IR is lethal. However, mice have been produced with tissue-specific KO of the IR—the FIRKO, MIRKO,

and SIRKO mice with the IR knocked out respectively in fat, muscle, and skin cells. FIRKO mice have much reduced fat tissue and an extended lifespan (73), but data on cancer is lacking. SIRKO mice, however, have reduced rates of melanoma (74), and MIRKO mice have reduced rates of colon cancer (75).

Phosphatase and tensin homolog which reverses the conversion of phosphatidylinositol (3,4)-bisphosphate to phosphatidylinositol (3,4,5)-trisphosphate catalyzed by PI3K is recognized as a tumor suppressor gene (76). Mutations and deletions in the *PTEN* gene or the downregulation of phosphatase and tensin homolog have been reported in various malignant tumors (77) and in leukemia (78). Conversely mutations in PI3K are also often linked to cancer but in this case the mutations causing cancer increase the activity of the PI3K. Pharmacological inhibition of PI3K by wortmanin or LY294002 both result in inhibition of proliferation in cell culture (79). Cancers that are resistant to the inhibitory effects of caloric restriction tend to have mutations in the insulin signaling pathway—particularly in PI3K (80), suggesting the anticancer effects of caloric restriction are contingent on lowered insulin levels and an intact signaling pathway to transduce these lowered levels into modulated levels of apoptosis, and perhaps other effects such as altered proliferation (80). Studies of isoforms of PI3K subunit p110 suggest a link to cancer development (81,82) and there is evidence that the risk of development of cancer appears to hinge on the balance of the insulin receptor isoforms, with IR-A being especially overexpressed in some cancers (83–85).

As might be expected, knocking out SKP2 stops p27 being tagged for degradation. This p27 then acts as a cell proliferation repressor and these mice have much reduced adipocyte cell numbers (61,86) and reduced β -cell numbers (86,87) but also reduced susceptibility to cancer. These effects on proliferation of adipose tissue can be eliminated by simultaneous KO of p27, showing that the effect of SKP2 on adipogenesis is mediated exclusively via p27 (61). In contrast knocking out p27 alone

results in tissue proliferation. SKP2 is frequently overexpressed and/or p27 repressed in a variety of human cancers (88) including prostate cancer (89–91), cervical cancer (92), thyroid cancer (93), colorectal cancer (94), breast cancer (95,96), lung cancer (97), and leukemia (98). Compounds inhibiting SKP2 are currently under exploration as novel antitumor agents (87,99). While the link to SKP2 is often associated with lowered p27 levels, it has been suggested that SKP2 may also promote tumorigenesis by inhibiting p53-mediated apoptosis (100,101).

An additional factor that may potentially be important in this signaling pathway in obesity is IGF-1 which binds to both the IGF-1R and IRs (Figure 1). Although there is a stimulatory effect of insulin on IGF-1 production by adipocytes, which probably has an autocrine/paracrine role in stimulating growth of adipose tissue under conditions of overnutrition, circulating IGF-1 levels are decreased in obese subjects (102–105). This reduction in IGF-1 would be expected to have a protective effect against cancers (106). However, circulating IGF-1 is carried by a number of binding proteins (IGF-binding proteins (IGFBPs)), some of which enhance its activity (e.g., IGFBP-3) whereas others inhibit it (e.g., IGFBP-1). Production of the inhibitory IGFBP-1 in the liver is strongly reduced by insulin (107). Hence, the balance of the effects of obesity on bioactivity are unclear. It has been recently suggested that the overall reduction in IGF-1 levels in the obese is offset completely by the reduction in IGFBP-1 (108) leading to no overall effect of obesity on bioactive levels of IGF-1. Moreover, there is no evidence that the associations between both IGF-1 and the IGFBPs and obesity vary among ethnic groups.

To summarize, the evidence strongly implicates several elements of the insulin signaling pathway as primary mediators of susceptibility to cancer. Elevated insulin and increased insulin resistance in obesity may then stimulate this pathway causing the increased cancer risk. The complexity of the intracellular pathways that may mediate these links combined

with tissue specific and potentially ethnic variations in the expression of the different receptor isoforms, substrate proteins, and other regulatory components of the pathways, provides a potential explanation of why different tissues and different ethnic groups are differentially susceptible to the effects of globally elevated circulating insulin levels resulting from obesity.

SUMMARY: WHY DO THESE LINKAGES EXIST AND WHAT ARE THE IMPLICATIONS?

We suggest that the link between obesity and cancer that is mediated via tissue insulin exposure, may be an unwanted side effect of insulin responding to elevated nutrient flux. Elevated insulin may stimulate cellular proliferation in fat cells and pancreatic β -cells (87). This mechanism ensures additional insulin production and also provides additional storage for the increased nutrient load (57,61). This may have substantial advantages because it provides cells that can hold on to ingested fat and prevent its ectopic distribution elsewhere in the body. It is notable that African Americans that have elevated insulin in obesity and increased cancer risk have reduced risk of developing fatty liver disease even at an early age (15), while hispanics are particularly prone to fatty liver disease. Supporting our hypothesis some of the ethnic variation in susceptibility to fatty liver disease has been traced to polymorphic variation in the adiponutrin gene *PNPLA3* (Patatin-like phospholipase domain-containing protein 3) (109) and this gene has been linked to insulin secretion (110). This is important because it suggests that reducing levels of insulin in obesity as a strategy to prevent obesity-related cancers may have the unwanted side effect of reducing fat cell proliferation and promotion of fatty liver disease, and other ectopic fat deposition, unless it is combined with additional interventions to limit nutrient influx. However, the effects of insulin on cellular proliferation depends on specific tissue distributions of the various regulatory components of insulin signaling. Consequently, tissue-to-tissue variation in the stimulation of

these diverse pathways might explain the tissue-dependent variable risks of developing cancer in response to obesity (Table 1). Moreover, we speculate that the ethnic variation in the risk of developing cancer might also be traced to differences in this signaling cascade.

DISCLOSURE

The authors declared no conflict of interest.

© 2010 The Obesity Society

REFERENCES

1. Kain J, Uauy R, Vio F, Albala C. Trends in overweight and obesity prevalence in Chilean children: comparison of three definitions. *Eur J Clin Nutr* 2002;56:200–204.
2. Likitmasku S, Kiattisathavee P, Chaichanwatanakul K et al. Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. *J Pediatr Endocrinol Metab* 2003;16:71–77.
3. Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. *Int J Obes Relat Metab Disord* 2000;24:807–818.
4. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. *JAMA* 2002;288:1723–1727.
5. Yun S, Zhu BP, Black W, Brownson RC. A comparison of national estimates of obesity prevalence from the behavioral risk factor surveillance system and the National Health and Nutrition Examination Survey. *Int J Obes (Lond)* 2006;30:164–170.
6. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA* 2006;295:1549–1555.
7. Sturm R. Increases in morbid obesity in the USA: 2000–2005. *Public Health* 2007;121:492–496.
8. Lobstein T, Jackson-Leach R. Child overweight and obesity in the USA: prevalence rates according to IOTF definitions. *Int J Pediatr Obes* 2007;2:62–64.
9. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003–2006. *JAMA* 2008;299:2401–2405.
10. The Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009;373:1089–1096.
11. Pi-Sunyer FX. Health implications of obesity. *Am J Clin Nutr* 1991;53:1595S–1603S.
12. Pi-Sunyer FX. Medical hazards of obesity. *Ann Intern Med* 1993;119:655–660.
13. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;24:683–689.
14. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387–1395.
15. Schwimmer JB, Deutsch R, Kahen T et al. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006;118:1388–1393.
16. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer* 2004;4:579–591.
17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625–1638.
18. NEEL JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? *Am J Hum Genet* 1962;14:353–362.
19. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. *Am J Med* 1988;84:739–749.
20. Lev-Ran A. Human obesity: an evolutionary approach to understanding our bulging waistline. *Diabetes Metab Res Rev* 2001;17:347–362.
21. Lev-Ran A. Thrifty genotype: how applicable is it to obesity and type 2 diabetes? *Diabetes Rev* 1999;7:1–22.
22. Chakravarthy MV, Booth FW. Eating, exercise, and “thrifty” genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. *J Appl Physiol* 2004;96:3–10.
23. Prentice AM, Rayco-Solon P, Moore SE. Insights from the developing world: thrifty genotypes and thrifty phenotypes. *Proc Nutr Soc* 2005;64:153–161.
24. Prentice AM. Early influences on human energy regulation: thrifty genotypes and thrifty phenotypes. *Physiol Behav* 2005;86:640–645.
25. Eknoyan G. A history of obesity, or how what was good became ugly and then bad. *Adv Chronic Kidney Dis* 2006;13:421–427.
26. Wells JC. The evolution of human fatness and susceptibility to obesity: an ethological approach. *Biol Rev Camb Philos Soc* 2006;81:183–205.
27. Speakman JR. Thrifty genes for obesity and the metabolic syndrome--time to call off the search? *Diab Vasc Dis Res* 2006;3:7–11.
28. Speakman JR. A nonadaptive scenario explaining the genetic predisposition to obesity: the “predation release” hypothesis. *Cell Metab* 2007;6:5–12.
29. Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the “drifty gene” hypothesis. *Int J Obes (Lond)* 2008;32:1611–1617.
30. Benyshek DC, Watson JT. Exploring the thrifty genotype’s food-shortage assumptions: a cross-cultural comparison of ethnographic accounts of food security among foraging and agricultural societies. *Am J Phys Anthropol* 2006;131:120–126.
31. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. *Nat Rev Cancer* 2004;4:519–527.
32. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. *Horm Metab Res* 2003;35:694–704.
33. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. *J Clin Endocrinol Metab* 2003;88:1417–1427.
34. Tannenbaum A. Genesis and growth of tumors. II. Effects of caloric restriction per se. *Cancer Res* 1942;2:460–467.
35. Tannenbaum A. The dependence of tumor formation on the degree of caloric restriction. *Cancer Res* 1945;5:609–615.
36. Ross MH, Bras G. Tumor incidence patterns and nutrition in the rat. *J Nutr* 1965;87:245–260.
37. Cheney KE, Liu RK, Smith GS et al. Survival and disease patterns in C57BL/6J mice subjected to undernutrition. *Exp Gerontol* 1980;15:237–258.
38. Weindruch R, Walford RL. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. *Science* 1982;215:1415–1418.
39. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B et al. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. *Proc Natl Acad Sci USA* 1999;96:9995–9999.
40. Volk MJ, Pugh TD, Kim M et al. Dietary restriction from middle age attenuates age-associated lymphoma development and interleukin 6 dysregulation in C57BL/6 mice. *Cancer Res* 1994;54:3054–3061.
41. Spindler SR. Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. *Mech Ageing Dev* 2005;126:960–966.
42. Freedman DS, Srinivasan SR, Burke GL et al. Relation of body fat distribution to hyperinsulinemia in children and adolescents: the Bogalusa Heart Study. *Am J Clin Nutr* 1987;46:403–410.
43. Gower BA, Nagy TR, Trowbridge CA, Dezenberg C, Goran MI. Fat distribution and insulin response in prepubertal African American and white children. *Am J Clin Nutr* 1998;67:821–827.
44. Ku CY, Gower BA, Hunter GR, Goran MI. Racial differences in insulin secretion and sensitivity in prepubertal children: role of physical fitness and physical activity. *Obes Res* 2000;8:506–515.
45. Gower BA, Granger WM, Franklin F, Shewchuk RM, Goran MI. Contribution of insulin secretion and clearance to glucose-induced insulin concentration in african-american and caucasian children. *J Clin Endocrinol Metab* 2002;87:2218–2224.
46. Goran MI, Bergman RN, Cruz ML, Watanabe R. Insulin resistance and associated compensatory responses in african-american and Hispanic children. *Diabetes Care* 2002;25:2184–2190.
47. Bayascas JR. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. *Cell Cycle* 2008;7:2978–2982.
48. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. *Cardiovasc Res* 2008;79:238–248.
49. Fritsche L, Weigert C, Häring HU, Lehmann R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver--implications for health and disease. *Curr Med Chem* 2008;15:1316–1329.
50. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. *Diabetologia* 2004;47:170–184.
51. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. *Biochem Biophys Res Commun* 1989;159:312–316.

52. Leibiger B, Leibiger IB, Moede T *et al*. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. *Mol Cell* 2001;7:559–570.
53. Sciacca L, Prisco M, Wu A *et al*. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. *Endocrinology* 2003;144:2650–2658.
54. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. *Diabetes Metab Res Rev* 2001;17:363–373.
55. Serrano R, Villar M, Martínez C *et al*. Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. *J Mol Endocrinol* 2005;34:153–161.
56. Mirza AM, Gysin S, Malek N *et al*. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. *Mol Cell Biol* 2004;24:10868–10881.
57. Auld CA, Caccia CD, Morrison RF. Hormonal induction of adipogenesis induces Skp2 expression through PI3K and MAPK pathways. *J Cell Biochem* 2007;100:204–216.
58. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. *Cancer Res* 2007;67:4149–4156.
59. Wang Q, Zhou Y, Wang X, Evers BM. p27 Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. *Cell Death Differ* 2008;15:908–919.
60. Kossatz U, Dietrich N, Zender L *et al*. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. *Genes Dev* 2004;18:2602–2607.
61. Cooke PS, Holsberger DR, Cimafranca MA *et al*. The F box protein S phase kinase-associated protein 2 regulates adipose mass and adipocyte number in vivo. *Obesity (Silver Spring)* 2007;15:1400–1408.
62. Gilmore TD. Introduction to NF- κ B: players, pathways, perspectives. *Oncogene* 2006;25:6680–6684.
63. Brasier AR. The NF- κ B regulatory network. *Cardiovasc Toxicol* 2006;6:111–130.
64. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. *Oncogene* 2004;23:3151–3171.
65. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell* 2007;12:9–22.
66. Holgado-Madruga M, Emler DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. *Nature* 1996;379:560–564.
67. Selman C, Lingard S, Choudhury AI *et al*. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. *FASEB J* 2008;22:807–818.
68. Withers DJ, Gutierrez JS, Towery H *et al*. Disruption of IRS-2 causes type 2 diabetes in mice. *Nature* 1998;391:900–904.
69. Withers DJ, Burks DJ, Towery HH *et al*. Irs-2 coordinates Igf-1 receptor-mediated β -cell development and peripheral insulin signalling. *Nat Genet* 1999;23:32–40.
70. Choudhury AI, Heffron H, Smith MA *et al*. The role of insulin receptor substrate 2 in hypothalamic and β cell function. *J Clin Invest* 2005;115:940–950.
71. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. *Science* 2007;317:369–372.
72. Selman C, Lingard S, Gems D, Partridge L, Withers DJ. Comment on “Brain IRS2 signaling coordinates life span and nutrient homeostasis”. *Science* 2008;320:1012; author reply 1012.
73. Blüher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science* 2003;299:572–574.
74. Wertheimer E, Sirota I, Mizrahi S *et al*. The skin specific insulin receptor knockout (SIRKO) mouse: A new outlook on diabetes complications and skin cancer *J Invest Dermatol* 2008;128:S131.
75. Ealey KN, Lu S, Lau D, Archer MC. Reduced susceptibility of muscle-specific insulin receptor knockout mice to colon carcinogenesis. *Am J Physiol Gastrointest Liver Physiol* 2008;294:G679–G686.
76. Simpson L, Parsons R. PTEN: life as a tumor suppressor. *Exp Cell Res* 2001;264:29–41.
77. Kurasawa Y, Shiiba M, Nakamura M *et al*. PTEN expression and methylation status in oral squamous cell carcinoma. *Oncol Rep* 2008;19:1429–1434.
78. Maeng HY, Kim JY, Cheong JW *et al*. Expression of Skp2 protein correlates with constitutive phosphorylation of PTEN and Akt/PKB in acute myelogenous leukemia. *Blood* 2003;102:869A.
79. Pene F, Claessens YE, Muller O *et al*. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. *Oncogene* 2002;21:6587–6597.
80. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. *Nature* 2009;458:725–731.
81. Foukas LC, Claret M, Pearce W *et al*. Critical role for the p110 α phosphoinositide-3-OH kinase in growth and metabolic regulation. *Nature* 2006;441:366–370.
82. Jia S, Liu Z, Zhang S *et al*. Essential roles of PI(3)K-p110 β in cell growth, metabolism and tumorigenesis. *Nature* 2008;454:776–779.
83. Frasca F, Pandini G, Scalia P *et al*. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Mol Cell Biol* 1999;19:3278–3288.
84. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. *Horm Metab Res* 2003;35:778–785.
85. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. *Curr Pharm Des* 2007;13:671–686.
86. Sakai T, Sakaue H, Nakamura T *et al*. Skp2 controls adipocyte proliferation during the development of obesity. *J Biol Chem* 2007;282:2038–2046.
87. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. *Cancer* 2008;112:1415–1424.
88. Zhong L, Georgia S, Tschen SI *et al*. Essential role of Skp2-mediated p27 degradation in growth and adaptive expansion of pancreatic β cells. *J Clin Invest* 2007;117:2869–2876.
89. Shibahara T, Onishi T, Franco OE, Arima K, Sugimura Y. Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells. *Anticancer Res* 2005;25:1881–1888.
90. van Duijn PW, Trapman J. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells. *Prostate* 2006;66:749–760.
91. Shapira M, Ben-Izhak O, Slotky M *et al*. Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer. *J Urol* 2006;176:2285–2289.
92. Kim JY, Lim SJ, Kim HJ *et al*. Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. *Int J Gynecol Pathol* 2007;26:242–247.
93. Chiappetta G, De Marco C, Quintiero A *et al*. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. *Endocr Relat Cancer* 2007;14:405–420.
94. Uddin S, Ahmed M, Bavi P *et al*. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. *Cancer Res* 2008;68:3379–3388.
95. Sonoda H, Inoue H, Ogawa K *et al*. Significance of skp2 expression in primary breast cancer. *Clin Cancer Res* 2006;12:1215–1220.
96. Wei-Wei H, Xiao-Xiang G, Long-Bang C. The cross-talk between p27(kip1) and its interacting molecules in breast cancer cells. *Prog Biochem and Biophys* 2008;35:637–642.
97. Yang CL, Sun TH, He WX, Zhou QX, Chen S. Single and joint effects of pesticides and mercury on soil urease. *J Environ Sci (China)* 2007;19:210–216.
98. Andreu EJ, Lledó E, Poch E *et al*. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. *Cancer Res* 2005;65:3264–3272.
99. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. *Nat Rev Cancer* 2008;8:253–267.
100. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. *Mol Cell* 2008;29:217–231.
101. Reed SI. Deathproof: new insights on the role of skp2 in tumorigenesis. *Cancer Cell* 2008;13:88–89.
102. Maccario M, Ramunni J, Oleandri SE *et al*. Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. *Int J Obes Relat Metab Disord* 1999;23:612–618.

103. Gram IT, Norat T, Rinaldi S *et al*. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. *Int J Obes (Lond)* 2006;30:1623–1631.
104. Lukanova A, Lundin E, Zeleniuch-Jacquotte A *et al*. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. *Eur J Endocrinol* 2004;150:161–171.
105. Toledo-Corral CM, Roberts CK, Shaibi GQ *et al*. Insulin-like growth factor-I is inversely related to adiposity in overweight Latino children. *J Pediatr Endocrinol Metab* 2008;21:855–864.
106. Laron Z. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. *Hormones (Athens)* 2008;7:24–27.
107. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. *J Clin Endocrinol Metab* 1992;74:1355–1360.
108. Zhao R, Macdonald K, Casson AG. Insulin-like growth factor type I receptor gene expression and obesity in esophageal adenocarcinoma. *Mol Carcinog* 2009;48:982–988.
109. Romeo S, Kozlitina J, Xing C *et al*. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008;40:1461–1465.
110. Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M. Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. *Eur J Endocrinol* 2008;159:577–583.